Frontlight ResearchEarly access
Active, not recruitingPhase 3
Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France33 sites in 1 countryChoose a country to see its sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 130 people, planned
- Started
- 6 Apr 2021
- Expected to end
- 6 Apr 2027
- Type of study
- Interventional
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- Males or females ≥ 18 and ≤ 75 years
- Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
- Colonoscopy (already done or scheduled before randomization) within the last 5 years (or within 6 months if IBD is associated to PSC) with neither cancer nor all-grade dysplasia or endoscopy of the ileal reservoir (already done or scheduled before randomization) within the last 2 years in patients with ileo-anal anastomosis
- ALP ≥ 1.5 ULN
- Traitement par l'AUDC (13-23 mg/kg/j) depuis ≥ 6 mois avant l'inclusion (Arrondi à l’unité le plus proche, par exemple 12.5 mg/kg/j arrondi à 13 mg/kg/j)
- Using contraceptive in women of childbearing potential. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly
- Affiliation to a social security system (AME excepted)
- Signed informed consent
Who cannot take part
- Treatment with a fibrate within the last 3 months inclusion
- Dosage change of treatment for associated IBD ≤3 months prior to inclusion
- History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis or suspected cholangiocarcinoma
- Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
- Prior liver transplantation
- Current active IBD defined as either current use of systemic corticosteroid therapy > 10 mg/day or budesonide > 3 mg /day or immunosuppressive drugs (cyclosporine, tacrolimus, mycophenolate mofetil, mTor inhibitors, JAK inhibitors) or a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn’s Disease Activity Index (CDAI) > 150 in patients with Crohn’s disease (CD)
- Current or history of colonic cancer or all-grade dysplasia described at the last colonoscopy (Patients with a history of colon cancer and treated by total colectomy without recurrence for at least 5 years are eligible)
- Any other cause of liver damage ((positive test for HBV, HCV, or HIV, excessive alcohol consumption, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, celiac disease
- History of or established or suspected hepatobiliary carcinoma
- Current or recent history (within 2 years) of clinically detectable Ascites or digestive hemorrhage
- History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to Screening)
- Known hypersensitivity to bezafibrate, any of the components of Befizal© or other fibrates
- Current or recent history (within 2 years) of Autoimmune hepatitis defined by the presence of interface hepatitis documented on liver biopsy and at least 1 of the 2 following criteria: 1) AST or ALT > 5 ULN, 2) Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
- Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis (elevated serum IgG4 > 4 ULN)
- Patient with congenital galactosemia, glucose malabsorption, or lactase deficiency because of presence of lactose in 400 mg SR tablets of bezafibrate and in placebo tablets
- Renal insufficiency (clearance < 60 ml/min or serum creatinine level > 130 μmole/L)
- Total bilirubin in the last 3 months > 50 μmole/L (3 mg/dl)
- Gilbert syndrome defined as unconjugated bilirubinemia > LSN in the last 3 months (according to the laboratory reference value)
- Albumin in the last 3 months < LLN (according to the laboratory reference value)
- Platelets count in the last 3 months < 100000/mm3
- ALT or AST > 5 ULN in the last 3 months
- Child-Pugh score B or C
- Any severe comorbidity that may reduce life expectancy
- Known photosensitivity or photoallergy reactions to fibrate
- Pregnancy (or desire for)
- Breastfeeding
- Participation in any other interventional study or in the exclusion period any other interventional study
- Prothrombin index in the last 3 months < 70%
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the efficacy of 24-month treatment with bezafibrate (400 mg SR/d) versus placebo in addition to standard UDCA therapy in primary sclerosing cholangitis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER)
- Record updated
- 9 November 2026